Compare Amgen, Inc. (AMGN) vs SOLAI Limited (SLAI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs SOLAI Limited — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while SOLAI Limited trades at $3.34 (market cap $15.52M). The key difference: Amgen, Inc. is far larger — about 12636.6× SOLAI Limited's market cap, and Amgen, Inc. pays a 2.77% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| AMGN | SLAI | |
|---|---|---|
Market Cap | $196.12B | $15.52M |
Sector | Health | Technology |
52-Week High | $388.16 | $30.66 |
52-Week Low | $271.18 | $2.74 |
Enterprise Value | $241.41B | $15.16M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
SLAI trades at $3.34, up 7.05% today, but technical indicators signal a bearish trend with support at $3. The company reported a net loss of $33.88M in 2025, with negative profit margins and ROE. Recent news includes a reverse stock split and a going-private proposal, while the sole analyst coverage is a Hold rating.
The outlook remains highly speculative due to persistent losses and NYSE listing concerns. Risks include financial instability and execution challenges in AI infrastructure. Upside depends on successful acquisitions and product launches, but the stock is suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
